azelnidipine has been researched along with candesartan in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hirooka, Y; Kishi, T; Ogawa, K; Shinohara, K; Sunagawa, K; Utsumi, H; Yasukawa, K | 1 |
| Daikuhara, H; Ishida, T; Kikuchi, F | 1 |
| Izumikawa, Y; Kato, H; Kojima, K; Kubo, E; Nagura, M; Nosaka, H; Shima, T; Shimada, M; Shiraishi, T; Tanemoto, M; Tomioka, S; Uchida, S; Ueda, S; Yano, H | 1 |
1 trial(s) available for azelnidipine and candesartan
| Article | Year |
|---|---|
The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Azetidinecarboxylic Acid; Benzimidazoles; Biomarkers; Biphenyl Compounds; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Chi-Square Distribution; Diabetes Mellitus, Type 2; Dihydropyridines; Drug Therapy, Combination; Female; Glycated Hemoglobin; Heart Rate; Humans; Hypertension; Imidazoles; Japan; Male; Middle Aged; Tetrazoles; Time Factors; Treatment Outcome | 2012 |
2 other study(ies) available for azelnidipine and candesartan
| Article | Year |
|---|---|
Combination therapy of olmesartan and azelnidipine inhibits sympathetic activity associated with reducing oxidative stress in the brain of hypertensive rats.
Topics: Animals; Antihypertensive Agents; Azetidinecarboxylic Acid; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Brain; Calcium Channel Blockers; Dihydropyridines; Disease Models, Animal; Drug Therapy, Combination; Hypertension; Imidazoles; Male; Olmesartan Medoxomil; Oxidative Stress; Rats; Rats, Inbred SHR; Tetrazoles | 2012 |
Blood pressure control and satisfaction of hypertensive patients following a switch to combined drugs of an angiotensin receptor blocker and a calcium channel blocker in clinical practice of nephrology.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Azetidinecarboxylic Acid; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Drug Combinations; Drug Costs; Drug Substitution; Female; Humans; Hypertension; Imidazoles; Male; Medication Adherence; Middle Aged; Nephrology; Patient Satisfaction; Practice Patterns, Physicians'; Renal Insufficiency, Chronic; Retrospective Studies; Surveys and Questionnaires; Telmisartan; Tetrazoles; Valsartan | 2015 |